June 29, 2020 / 6:54 AM / 13 days ago

BRIEF-Novartis Receives Japanese Health Ministry's Approval For Five Products

June 29 (Reuters) - Novartis AG:

* NOVARTIS RECEIVES SIMULTANEOUS APPROVAL FOR FIVE NEW PRODUCTS FROM JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE, OFFERING JAPANESE PATIENTS A BROAD RANGE OF NOVEL TREATMENT OPTIONS

* TABRECTA™ (CAPMATINIB, FORMERLY INC280), AN ORAL MET INHIBITOR FOR MET EXON 14 SKIPPING (METEX14) MUTATION-POSITIVE ADVANCED AND/OR RECURRENT UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)

* ENTRESTO® (SACUBITRIL VALSARTAN SODIUM HYDRATE) IN CHRONIC HEART FAILURE

* MAYZENT® (SIPONIMOD FUMARIC ACID) IN SECONDARY PROGRESSIVE MS

* ENERZAIR™ (GLYCOPYRRONIUM BROMIDE, INDACATEROL ACETATE, MOMETASONE FUROATE) AND ANDATECTURA® (INDACATEROL ACETATE, MOMETASONE FUROATE) IN DIFFERENT FORMS OF ASTHMA Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below